Longevity & AgingNew Drug Combo Boosts Tirzepatide Weight Loss by 4.5% While Targeting Brain and Muscle Health
OrsoBio presented new clinical data showing that its experimental drug TLC-6740, when added to tirzepatide, produced an extra 4.5% average weight loss over 24 weeks in people with obesity. Unlike GLP-1 drugs that reduce appetite, TLC-6740 works by increasing how much energy cells burn — targeting the other side of the calorie equation. The combination also improved insulin sensitivity, liver health, and body composition. A separate preclinical study on TLC-1180, OrsoBio's next-generation candidate, showed improvements in exercise capacity, lean mass preservation, and even partial restoration of memory in obese mice. The findings suggest mitochondrial protonophores could complement existing obesity drugs while addressing broader aging-related metabolic decline.
